HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. (Q38956398)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 May 2007

Language	Label	Description	Also known as
English	HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.	scientific article published on 11 May 2007

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

prophylactic vaccine

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Julianna Lisziewicz

2

object named as

Julianna Lisziewicz

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Anthony D Cristillo

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Leilei He

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Franco Lori

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Lindsey Galmin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Jeffrey N Trocio

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Tami Unangst

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Lucia Whitman

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Lauren Hudacik

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Nyasha Bakare

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Stephen Whitney

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Susana Restrepo

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Maria Grazi Ferrari

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

H K Chung

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Vaniambadi S Kalyanaraman

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Phillip Markham

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Ranajit Pal

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

0 references

publication date

11 May 2007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

Europe PubMed Central

7 September 2017

366

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

197-211

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17499328%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

DNA vaccination for HIV-1 and SIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Helping the CD8(+) T-cell response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Interleukin-18 modulates immune responses induced by HIV-1 Nef DNA prime/protein boost vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

DNA vaccines against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellu

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Development of a DNA-MVA/HIVA vaccine for Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Therapeutic vaccination for future management of HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

DermaVir: a novel topical vaccine for HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Control of viral rebound through therapeutic immunization with DermaVir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Topical DermaVir vaccine targeting dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

DermaVir, a novel HIV immunisation technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Immunopathogenesis of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Transcutaneous immunization with inactivated influenza virus induces protective immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

The moving target: mechanisms of HIV persistence during primary infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Vaccine-induced CD8+ central memory T cells in protection from simian AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.012

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38956398&oldid=1657485641"